essence semaglutide EASL 2026 Breaking! Phase 3 ESSENCE trial
Description
Higher doses of tirzepatide helped patients with obesity lose up to 22.5% of their body weight on average in late-stage studies
The goal should never be that someone has to be on something forever. Dr
Nearly 29% average body weight reduction
Psychological stress The emotional side of big body changes (and health anxiety about new medication) can add an extra trigger
Cardiovasc Drug Rev
If nausea or other GI side effects persist beyond 4-6 weeks despite dose stabilization, provider guidance should address whether to continue, adjust the formulation, or transition to an alternative
